Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Evoke Pharma (EVOK) over the last 5 years, with Q3 2025 value amounting to $38896.0.

  • Evoke Pharma's Cash from Financing Activities fell 9869.47% to $38896.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 6707.89%. This contributed to the annual value of $14.3 million for FY2024, which is 1210033.19% up from last year.
  • Latest data reveals that Evoke Pharma reported Cash from Financing Activities of $38896.0 as of Q3 2025, which was down 9869.47% from $24999.0 recorded in Q1 2025.
  • Over the past 5 years, Evoke Pharma's Cash from Financing Activities peaked at $13.1 million during Q1 2021, and registered a low of $24999.0 during Q1 2025.
  • Over the past 4 years, Evoke Pharma's median Cash from Financing Activities value was $313107.0 (recorded in 2021), while the average stood at $3.2 million.
  • As far as peak fluctuations go, Evoke Pharma's Cash from Financing Activities surged by 6140660.71% in 2021, and later crashed by 9966.86% in 2025.
  • Evoke Pharma's Cash from Financing Activities (Quarter) stood at $313107.0 in 2021, then soared by 2175.09% to $7.1 million in 2022, then crashed by 50.9% to $3.5 million in 2024, then crashed by 98.89% to $38896.0 in 2025.
  • Its Cash from Financing Activities was $38896.0 in Q3 2025, compared to $24999.0 in Q1 2025 and $3.5 million in Q4 2024.